Taltobulin

Summary

Taltobulin (HTI‑286) is an investigational antimitotic peptide derived from the marine natural product hemiasterlin. It belongs to the antineoplastic peptide class and acts as a tubulin‑binding agent that disrupts microtubule polymerisation, leading to cancer cell death. Developed for intravenous administration, it is being explored as a potent cytotoxic payload for antibody‑drug conjugates and as a stand‑alone anticancer agent.

Mechanism of Action

Taltobulin binds to the β‑tubulin subunit of microtubules, preventing polymerisation and causing mitotic arrest. This disruption triggers apoptosis in rapidly dividing cells. Cellular studies show that activation of the fibroblast growth factor‑1 (FGF1)/FGFR1 axis can reactivate AKT signalling, attenuating taltobulin‑induced apoptosis and reducing drug sensitivity. Inhibition of AKT, PI3K or FGFR1 restores cytotoxicity, highlighting a resistance pathway linked to growth‑factor signalling.

What the Research Shows

Pre‑clinical work demonstrates that taltobulin has sub‑nanomolar cytotoxic potency against a range of cancer cell lines and can be incorporated into antibody‑drug conjugates that selectively kill HER2‑positive cells while sparing antigen‑negative ones. Cellular models reveal that FGF1 protects breast cancer (MCF‑7) and FGFR1‑positive osteosarcoma cells from taltobulin‑induced death via ERK and AKT activation. Inhibition of FGFR1 or AKT reverses this protection, suggesting a resistance mechanism. Recent studies show that honokiol or an FGF‑ligand trap can block the FGF1/FGFR1 axis, preventing the emergence of taltobulin‑resistant clones. No human clinical trial data are reported; the compound remains investigational.

Reported Benefits

Taltobulin’s primary advantage is its extremely high potency, comparable to its natural counterpart hemiasterlin, making it a promising payload for targeted therapies such as ADCs. In vitro, ADCs bearing taltobulin achieve sub‑nanomolar killing of HER2‑expressing tumor cells with minimal activity against non‑target cells. Its synthetic accessibility enables rapid analogue generation and combination studies aimed at overcoming resistance pathways.

Limitations of the Evidence

Evidence for taltobulin is limited to cell‑culture and biochemical studies; no animal efficacy or safety data are presented in the cited literature. Resistance mediated by FGF1/FGFR1 signalling reduces its effectiveness in certain tumor contexts, and the need for co‑inhibition adds complexity. As an investigational agent, regulatory approval, dosing, and clinical efficacy remain undefined.

Safety Considerations

Direct safety information for taltobulin is absent from the abstracts. As a tubulin‑targeting agent, class‑related toxicities such as peripheral neuropathy, myelosuppression, and gastrointestinal effects are plausible, but have not been documented in pre‑clinical reports. The lack of in vivo data precludes definitive statements on tolerability or therapeutic window.

How It Is Administered

Taltobulin is formulated for intravenous delivery. In experimental settings it has been administered as a free compound in cell‑based assays and as a conjugated payload within antibody‑drug conjugates, both delivered by infusion.

Routes of Administration

Goals & Uses

• Prostate cancer treatmentOncologyLow
• Non-small cell lung cancer treatmentOncologyLow
• Antitumor activity in solid tumorsOncologyModerate
• Overcoming multidrug resistanceOncologyModerate

Contraindications

• Severe hepatic impairmentOrganModerateLiver function concerns
• Active uncontrolled infectionInfectious DiseaseModerate
• Pre-existing severe peripheral neuropathyNeurologicalHigh

Adverse Effects

• Peripheral neuropathyNeurologicalCommon
• AlopeciaDermatologicCommonHair loss
• Nausea/vomitingGastrointestinalCommon
• NeutropeniaHematologicUncommonLow neutrophil count
• FatigueGeneralCommonLow energy or tiredness
• Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers

Drug Interactions

• Other neurotoxic agents (e.g., platinum compounds, vinca alkaloids)Moderate
• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)Moderate

Population Constraints

• Pediatric patientsAgeRelative
• Pregnant womenReproductiveAbsolute
• Patients with severe renal impairmentOrgan ImpairmentRelative

Regulatory Status

• European UnionInvestigationalNo EMA approval or marketing authorization; investigational use only.
• United StatesInvestigationalEvaluated under IND in Phase I/II trials; development discontinued; no approved indication.
• United KingdomInvestigationalNo MHRA approval; not marketed in the UK.

Taltobulin has not received FDA, EMA, or MHRA approval for any indication. Clinical development was halted after Phase I/II trials; no active IND or regulatory pathway is currently known.

Evidence & Sources

• FGF1 Protects MCF-7 Cells against Taltobulin through Both the MEKs/ERKs and PI3K/AKT Signaling Pathway
  Journal ArticleLowSzymczyk J, et al.2023-01-01T00:00:00.000000Z
• Gateways to clinical trials
  Journal ArticleLowBayés M, Rabasseda X, Prous JR2004-01-01T00:00:00.000000Z
• FGF1 protects FGFR1-overexpressing cancer cells against drugs targeting tubulin polymerization by activating AKT via two independent mechanisms
  Journal ArticleLowSzymczyk J, et al.2022-01-01T00:00:00.000000Z
• Sponging off nature for new drug leads
  Journal ArticleModerateAndersen RJ2017-01-01T00:00:00.000000Z
• Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics
  Journal ArticleLowCharoenpattarapreeda J, et al.2020-01-01T00:00:00.000000Z
• Overcoming drug resistance of cancer cells by targeting the FGF1/FGFR1 axis with honokiol or FGF ligand trap
  Journal ArticleLowSzymczyk J, et al.2024-01-01T00:00:00.000000Z

Frequently Asked Questions